-
Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye drops, designed to delay myopia progression in children aged 6-12, has been accepted by the National Medical Products Administration (NMPA). The product targets children with spherical diopters ranging from -0.50D to -4.00D and astigmatism/anisometropia ≤…
-
Aspen Pharmacare’s 2024 Fiscal Report Shows Mixed Results Amid China’s VBP Impact
•
Aspen Pharmacare Holdings Ltd (JSE: APN), a leading South African pharmaceutical company, has reported its financial results for the fiscal year ending June 30, 2024. The company saw a 5% year-on-year (YOY) increase in revenues in constant currency terms, reaching ZAR 44.7 billion (USD 2.5 billion). However, EBITDA profits experienced…
-
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
•
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its footprint in the Chinese market with the full acquisition of Sandoz’s (SWX: SDZ) China subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. This acquisition will grant Aspen all commercial and intellectual property rights to the subsidiary’s existing…
